I. , Federation, IDF Diabetes Atlas, 2015.

F. S. Hough, D. D. Pierroz, C. Cooper, S. L. Ferrari, I. C. Bone et al., Diabetes Working, Mechanisms in endocrinology: mechanisms and evaluation of bone fragility in type 1 diabetes mellitus, Eur. J. Endocrinol, vol.174, issue.4, pp.127-165, 2016.

N. Napoli, M. Chandran, D. D. Pierroz, B. Abrahamsen, A. V. Schwartz et al., Diabetes Working, Mechanisms of diabetes mellitus-induced bone fragility, Nat. Rev. Endocrinol, vol.13, issue.4, pp.208-219, 2017.

D. E. Sellmeyer, R. Civitelli, L. C. Hofbauer, S. Khosla, B. Lecka-czernik et al., Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes, Diabetes, vol.65, issue.7, pp.1757-1766, 2016.

A. V. Schwartz, Diabetes, bone and glucose-lowering agents: clinical outcomes, Diabetologia, vol.60, issue.7, pp.1170-1179, 2017.

L. M. Coe, S. A. Tekalur, Y. Shu, M. J. Baumann, and L. R. Mccabe, Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation, J. Cell. Physiol, vol.230, issue.8, pp.1944-1953, 2015.

L. Y. Park-wyllie, M. M. Mamdani, D. N. Juurlink, G. A. Hawker, N. Gunraj et al., Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women, JAMA, vol.305, issue.8, pp.783-789, 2011.

K. J. Motyl, L. K. Mccauley, and L. R. Mccabe, Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival, J. Cell. Physiol, vol.227, issue.4, pp.1326-1334, 2012.

J. B. Furness, L. R. Rivera, H. J. Cho, D. M. Bravo, and B. Callaghan, The gut as a sensory organ, Nat. Rev. Gastroenterol. Hepatol, vol.10, issue.12, pp.729-740, 2013.

W. Creutzfeldt, The incretin concept today, Diabetologia, vol.16, issue.2, pp.75-85, 1979.

D. J. Drucker, The biology of incretin hormones, Cell Metab, vol.3, issue.3, pp.153-165, 2006.

A. M. Buchan, J. M. Polak, C. Capella, E. Solcia, and A. G. Pearse, Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man, Histochemistry, vol.56, issue.1, pp.37-44, 1978.

S. Sykes, L. M. Morgan, J. English, and V. Marks, Evidence for preferential stimulation of gastric inhibitory polypeptide secretion in the rat by actively transported carbohydrates and their analogues, J. Endocrinol, vol.85, issue.2, pp.201-207, 1980.

Y. M. Cho and T. J. Kieffer, K-cells and glucose-dependent insulinotropic polypeptide in health and disease, Vitam. Horm, vol.84, pp.111-150, 2010.

Y. Higashimoto, E. C. Opara, and R. A. Liddle, Dietary regulation of glucose-dependent insulinotropic peptide (GIP) gene expression in rat small intestine, Comp. Biochem. Physiol. Part C Pharmacol. Toxicol. Endocrinol, vol.110, issue.2, pp.207-214, 1995.

C. C. Tseng, L. A. Jarboe, and M. M. Wolfe, Regulation of glucose-dependent insulinotropic peptide gene expression by a glucose meal, Am. J. Physiol, vol.266, issue.5, pp.887-91, 1994.

E. L. Pacheco-pantoja, L. R. Ranganath, J. A. Gallagher, P. J. Wilson, and W. D. Fraser, Receptors and effects of gut hormones in three osteoblastic cell lines, BMC Physiol, vol.11, p.12, 2011.

R. J. Bollag, Q. Zhong, P. Phillips, L. Min, L. Zhong et al., Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors, Endocrinology, vol.141, issue.3, pp.1228-1235, 2000.

G. Mabilleau, C. Gaudin-audrain, N. Irwin, P. R. Flatt, M. F. Basle et al., Deficiency in glucose-dependent insulinotropic peptide receptor results in higher bone mass in male mice, Osteoporos. Int, vol.23, pp.407-415, 2012.

Q. Zhong, T. Itokawa, S. Sridhar, K. H. Ding, D. Xie et al., Effects of glucose-dependent insulinotropic peptide on osteoclast function, Am. J. Physiol. Endocrinol. Metab, vol.292, issue.2, pp.543-551, 2007.

E. Aoyama, I. Watari, K. A. Podyma-inoue, M. Yanagishita, and T. Ono, Expression of glucagon-like peptide-1 receptor and glucosedependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells, Int. J. Mol. Med, vol.34, issue.2, pp.475-482, 2014.

A. Mieczkowska, B. Bouvard, D. Chappard, and G. Mabilleau, Glucose-dependent insulinotropic polypeptide (GIP) directly affects collagen fibril diameter and collagen cross-linking in osteoblast cultures, Bone, vol.74, pp.29-36, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01392274

G. Mabilleau, R. Perrot, A. Mieczkowska, S. Boni, P. R. Flatt et al., Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption, Bone, vol.91, pp.102-112, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01392269

K. Tsukiyama, Y. Yamada, C. Yamada, N. Harada, Y. Kawasaki et al., Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion, Mol. Endocrinol, vol.20, issue.7, pp.1644-1651, 2006.

K. Suzuki, N. Harada, S. Yamane, Y. Nakamura, K. Sasaki et al., Transcriptional regulatory factor X6 (Rfx6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine K-cells and is involved in GIP hypersecretion in high fat diet-induced obesity, J. Biol. Chem, vol.288, issue.3, pp.1929-1938, 2013.

D. Nasteska, N. Harada, K. Suzuki, S. Yamane, A. Hamasaki et al., Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions, Diabetes, vol.63, issue.7, pp.2332-2343, 2014.

D. Xie, H. Cheng, M. Hamrick, Q. Zhong, K. H. Ding et al., Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover, Bone, vol.37, issue.6, pp.759-769, 2005.

C. Gaudin-audrain, N. Irwin, S. Mansur, P. R. Flatt, B. Thorens et al., Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice, Bone, vol.53, issue.1, pp.221-230, 2013.

A. Mieczkowska, N. Irwin, P. R. Flatt, D. Chappard, and G. Mabilleau, Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality, Bone, vol.56, issue.2, pp.337-342, 2013.

D. Flamez, A. Van-breusegem, L. A. Scrocchi, E. Quartier, D. Pipeleers et al., Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene, Diabetes, vol.47, issue.4, pp.646-652, 1998.

N. Pamir, F. C. Lynn, A. M. Buchan, J. Ehses, S. A. Hinke et al., Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis, Am. J. Physiol. Endocrinol. Metab, vol.284, issue.5, pp.931-940, 2003.

G. Mabilleau, Peptides, 2017.

R. A. Pederson, M. Satkunarajah, C. H. Mcintosh, L. A. Scrocchi, D. Flamez et al., Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/-mice, Diabetes, vol.47, issue.7, pp.1046-1052, 1998.

A. Mieczkowska, S. Mansur, B. Bouvard, P. R. Flatt, B. Thorens et al., Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength, Osteoporos. Int, vol.26, issue.1, pp.209-218, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01392271

E. E. Mulvihill, E. M. Varin, B. Gladanac, J. E. Campbell, J. R. Ussher et al., Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis, Cell Metab, vol.25, issue.1, pp.152-165, 2017.

N. Irwin and P. R. Flatt, Therapeutic potential for GIP receptor agonists and antagonists, Best Pract. Res. Clin. Endocrinol. Metab, vol.23, issue.4, pp.499-512, 2009.

G. Mabilleau, A. Mieczkowska, N. Irwin, Y. Simon, M. Audran et al., Chappard, Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties, Bone, vol.63, pp.61-68, 2014.

S. A. Mansur, A. Mieczkowska, B. Bouvard, P. R. Flatt, D. Chappard et al., Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus, J. Cell. Physiol, vol.230, issue.12, pp.3009-3018, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01392285

D. B. Henriksen, P. Alexandersen, N. H. Bjarnason, T. Vilsboll, B. Hartmann et al., Role of gastrointestinal hormones in postprandial reduction of bone resorption, J. Bone Miner. Res, vol.18, issue.12, pp.2180-2189, 2003.

A. Nissen, M. Christensen, F. K. Knop, T. Vilsboll, J. J. Holst et al., Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans, J. Clin. Endocrinol. Metab, vol.99, issue.11, pp.2325-2334, 2014.

S. S. Torekov, T. Harslof, L. Rejnmark, P. Eiken, J. B. Jensen et al., A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk, J. Clin. Endocrinol. Metab, vol.99, issue.4, pp.729-762, 2014.

J. P. Fortin, J. C. Schroeder, Y. Zhu, M. Beinborn, and A. S. Kopin, Pharmacological characterization of human incretin receptor missense variants, J. Pharmacol. Exp. Ther, vol.332, issue.1, pp.274-280, 2010.

C. Orskov, L. Rabenhoj, A. Wettergren, H. Kofod, and J. J. Holst, Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans, Diabetes, vol.43, issue.4, pp.535-539, 1994.

L. L. Baggio and D. J. Drucker, Biology of incretins: GLP-1 and GIP, vol.132, pp.2131-2157, 2007.

J. J. Holst and C. F. Deacon, Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors, Diabetologia, vol.48, issue.4, pp.612-615, 2005.

J. Y. Kim, S. K. Lee, K. J. Jo, D. Y. Song, D. M. Lim et al., Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes, Life Sci, vol.92, issue.10, pp.533-540, 2013.

M. Pereira, J. Jeyabalan, C. S. Jorgensen, M. Hopkinson, A. Al-jazzar et al., Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice, Bone, vol.81, pp.459-467, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01567148

B. Nuche-berenguer, S. Portal-nunez, P. Moreno, N. Gonzalez, A. Acitores et al., Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor, J. Cell. Physiol, vol.225, issue.2, pp.585-592, 2010.

M. A. Luque, N. Gonzalez, L. Marquez, A. Acitores, A. Redondo et al., Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes, J. Endocrinol, vol.173, issue.3, pp.465-473, 2002.

M. L. Villanueva-penacarrillo, E. Delgado, M. A. Trapote, A. Alcantara, F. Clemente et al., Glucagon-like peptide-1 binding to rat hepatic membranes, J. Endocrinol, vol.146, issue.1, pp.183-189, 1995.

C. Weston, J. Lu, N. Li, K. Barkan, G. O. Richards et al., Modulation of glucagon receptor pharmacology by receptor activity-modifying protein-2 (RAMP2), J. Biol. Chem, vol.290, issue.38, pp.23009-23022, 2015.

G. Mabilleau, A. Mieczkowska, N. Irwin, P. R. Flatt, and D. Chappard, Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor, J. Endocrinol, vol.219, issue.1, pp.59-68, 2013.

C. Yamada, Y. Yamada, K. Tsukiyama, K. Yamada, N. Udagawa et al., The murine glucagon-like peptide-1 receptor is essential for control of bone resorption, Endocrinology, vol.149, issue.2, pp.574-579, 2008.

L. W. Madsen, J. A. Knauf, C. Gotfredsen, A. Pilling, I. Sjogren et al., GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation, Endocrinology, vol.153, issue.3, pp.1538-1547, 2012.

G. Mabilleau, M. Pereira, and C. Chenu, Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists, J. Endocrinol, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02869252

C. Sanz, P. Vazquez, C. Blazquez, P. A. Barrio, M. Mdel et al., Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow, Am. J. Physiol. Endocrinol. Metab, vol.298, issue.3, pp.634-677, 2010.

J. He, C. Wang, Y. Sun, B. Lu, J. Cui et al., Exendin-4 protects bone marrow-derived mesenchymal stem cells against oxygen/glucose and serum deprivation-induced apoptosis through the activation of the cAMP/PKA signaling pathway and the attenuation of ER stress, Int. J. Mol. Med, vol.37, issue.4, pp.889-900, 2016.

Y. Feng, L. Su, X. Zhong, W. Guohong, H. Xiao et al., Exendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation, J. Mol. Endocrinol, vol.56, issue.3, pp.189-199, 2016.

X. K. Hu, X. H. Yin, H. Q. Zhang, C. F. Guo, and M. X. Tang, Liraglutide attenuates the osteoblastic differentiation of MC3T3E1 cells by modulating AMPK/mTOR signaling, Mol. Med. Rep, vol.14, issue.4, pp.3662-3668, 2016.

J. Meng, X. Ma, N. Wang, M. Jia, L. Bi et al., Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through beta-catenin, Stem Cell Rep, vol.6, issue.4, pp.579-591, 2016.

E. L. Pacheco-pantoja, J. P. Dillon, P. J. Wilson, W. D. Fraser, and J. A. Gallagher, c-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines, Purinergic Signal, vol.12, issue.4, pp.647-651, 2016.

X. Wu, S. Li, P. Xue, and Y. Li, Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3 K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving beta-catenin, Exp. Cell Res, 2017.

B. Nuche-berenguer, P. Moreno, P. Esbrit, S. Dapia, J. R. Caeiro et al., Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states, Calcif. Tissue Int, vol.84, issue.6, pp.453-461, 2009.

B. Nuche-berenguer, P. Moreno, S. Portal-nunez, S. Dapia, P. Esbrit et al., Villanueva-Penacarrillo, Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states, Regul. Pept, vol.159, issue.1-3, pp.61-66, 2010.

H. X. Sun, N. Lu, X. Luo, L. Zhao, and J. M. Liu, Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats, J. Diabetes, vol.7, issue.4, pp.584-588, 2015.

M. Nauck, A. Frid, K. Hermansen, A. B. Thomsen, M. During et al., Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study, Diabetes Obes. Metab, vol.15, issue.3, pp.204-212, 2013.

R. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy et al., One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial, Int. J. Clin. Pract, vol.65, issue.4, pp.397-407, 2011.

G. Mabilleau, D. Chappard, P. R. Flatt, and N. Irwin, Effects of anti-diabetic drugs on bone metabolism, Expert Rev. Endocrinol. Metab, vol.10, issue.6, pp.663-675, 2015.

X. Ma, J. Meng, M. Jia, L. Bi, Y. Zhou et al., Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats, J. Bone Miner. Res, vol.28, issue.7, pp.1641-1652, 2013.

N. Lu, H. Sun, J. Yu, X. Wang, D. Liu et al., Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes, PLoS One, vol.10, issue.7, p.132744, 2015.

A. Mizokami, Y. Yasutake, J. Gao, M. Matsuda, I. Takahashi et al., Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice, PLoS One, vol.8, issue.2, p.57375, 2013.

A. Mizokami, Y. Yasutake, S. Higashi, T. Kawakubo-yasukochi, S. Chishaki et al., Oral administration of osteocalcin improves glucose utilization by stimulating glucagon-like peptide-1 secretion, Bone, vol.69, pp.68-79, 2014.

G. Mabilleau, A. Mieczkowska, and D. Chappard, Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials, J. Diabetes, vol.6, issue.3, pp.260-266, 2014.

B. Su, H. Sheng, M. Zhang, L. Bu, P. Yang et al., Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials, Endocrine, vol.48, issue.1, pp.107-115, 2015.

J. H. Driessen, R. M. Henry, H. A. Van-onzenoort, A. Lalmohamed, A. M. Burden et al., Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis, Calcif. Tissue Int, vol.97, issue.2, pp.104-112, 2015.

J. H. Driessen, H. A. Van-onzenoort, J. Starup-linde, R. Henry, A. M. Burden et al., Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs, Calcif. Tissue Int, vol.97, issue.5, pp.506-515, 2015.

S. A. Paschou, A. D. Dede, P. G. Anagnostis, A. Vryonidou, D. Morganstein et al., Type 2 diabetes and osteoporosis: a guide to optimal management, J. Clin. Endocrinol. Metab, vol.102, issue.10, pp.3621-3634, 2017.

V. K. Bhat, B. D. Kerr, P. R. Flatt, and V. A. Gault, A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties, Biochem. Pharmacol, vol.85, issue.11, pp.1655-1662, 2013.

V. K. Bhat, B. D. Kerr, S. Vasu, P. R. Flatt, and V. A. Gault, A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice, Diabetologia, vol.56, issue.6, pp.1417-1424, 2013.

J. W. Day, N. Ottaway, J. T. Patterson, V. Gelfanov, D. Smiley et al., A new glucagon and GLP-1 co-agonist eliminates obesity in rodents, vol.5, pp.749-757, 2009.

B. Finan, T. Ma, N. Ottaway, T. D. Muller, K. M. Habegger et al.,

G. Mabilleau, Peptides, 2017.

. Tschop, Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans, Sci. Transl. Med, vol.5, issue.209, pp.209-151, 2013.

B. Finan, B. Yang, N. Ottaway, D. L. Smiley, T. Ma et al., A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents, vol.21, pp.27-36, 2015.

K. Fosgerau, L. Jessen, J. L. Tolborg, T. Osterlund, K. Schaeffer-larsen et al., The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db/db mice, Diabetes Obes. Metab, vol.15, issue.1, pp.62-71, 2013.

V. A. Gault, V. K. Bhat, N. Irwin, and P. R. Flatt, A novel glucagon-like peptide-1 (GLP-1)/ glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice, J. Biol. Chem, vol.288, issue.49, pp.35581-35591, 2013.

A. Hasib, M. T. Ng, V. A. Gault, D. Khan, V. Parthsarathy et al., An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice, Diabetologia, vol.60, issue.3, pp.541-552, 2017.

N. Irwin, V. Pathak, and P. R. Flatt, A novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat-fed mice, Diabetes, vol.64, issue.8, pp.2996-3009, 2015.

A. Pocai, P. E. Carrington, J. R. Adams, M. Wright, G. Eiermann et al., Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, vol.58, issue.10, pp.2258-2266, 2009.

L. B. Jensen, F. Quaade, and O. H. Sorensen, Bone loss accompanying voluntary weight loss in obese humans, J. Bone Miner. Res, vol.9, issue.4, pp.459-463, 1994.

J. A. Langlois, M. E. Mussolino, M. Visser, A. C. Looker, T. Harris et al., Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study, Osteoporos. Int, vol.12, issue.9, pp.763-768, 2001.

J. P. Frias, E. J. Bastyr-3rd, L. Vignati, M. H. Tschop, C. Schmitt et al., The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes, Cell Metab, vol.26, issue.2, pp.343-352, 2017.

S. A. Mansur, A. Mieczkowska, P. R. Flatt, B. Bouvard, D. Chappard et al., A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus, Bone, vol.87, pp.102-113, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01392261